Prediction of high-flow nasal cannula outcomes at the early phase using the modified respiratory rate oxygenation index.
BMC Pulm Med
; 22(1): 227, 2022 Jun 13.
Article
in English
| MEDLINE | ID: covidwho-1885300
ABSTRACT
BACKGROUND:
This study was designed to explore the early predictive value of the respiratory rate oxygenation (ROX) index modified by PaO2 (mROX) in high-flow nasal cannula (HFNC) therapy in patients with acute hypoxemia respiratory failure (AHRF).METHOD:
Seventy-five patients with AHRF treated with HFNC were retrospectively reviewed. Respiratory parameters at baseline and 2 h after HFNC initiation were analyzed. The predictive value of the ROX (ratio of pulse oximetry/FIO2 to respiratory rate) and mROX (ratio of arterial oxygen /FIO2 to respiratory rate) indices with two variations by adding heart rate to each index (ROX-HR and mROX-HR) was evaluated.RESULTS:
HFNC therapy failed in 24 patients, who had significantly higher intensive care unit (ICU) mortality and longer ICU stay. Both the ROX and mROX indices at 2 h after HFNC initiation can predict the risk of intubation after HFNC. Two hours after HFNC initiation, the mROX index had a higher area under the receiver operating characteristic curve (AUROC) for predicting HFNC success than the ROX index. Besides, baseline mROX index of greater than 7.1 showed a specificity of 100% for HFNC success.CONCLUSION:
The mROX index may be a suitable predictor of HFNC therapy outcomes at the early phase in patients with AHRF.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiratory Insufficiency
/
Noninvasive Ventilation
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
BMC Pulm Med
Year:
2022
Document Type:
Article
Affiliation country:
S12890-022-02017-8
Similar
MEDLINE
...
LILACS
LIS